|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment显示文摘Hepatocellular carcinoma(HCC)is the fifth most common cause of cancer in the world.According to Barcelona Clinic Liver Cancer modified criteria,patients with early stage disease are candidate to radiofrequency ablation(RFA),while patients with intermediate stage HCC are usually treated by transarterial chemoembolization(TACE).TACE and RFA induce a transient devascularisation effect followed by strong neoangiogenic stimulus.In fact,after these procedures,it has been demonstrated an up-regulation of pro-angiogenic and growth factors such as vascular endothelial growth factor-A,which might contribute to accelerated progression in patients with incomplete response.Several studies have demonstrated that MAP-kinase and AKT pathways,in addition to neo-angiogenesis,have an important role in the development of HCC.In advanced HCC,anti-angiogenic therapy and tyrosine kinases inhibitors showed potential clinical benefit.Actually,a number of clinical studies are ongoing testing these agents in combination with TACE or RFA.In this paper,we have reviewed the most recent preclinical and clinical results of such trials. | Girolamo Ranieri Ilaria Marech Vito Lorusso Veronica Goffredo Angelo Paradiso Domenico Ribatti Cosmo Damiano Gadaleta | 2014 | World Journal of Gastroenterology2014，20，2： | 14 |
| 2 | Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer显示文摘AIM: To identify suitable biomarkers of response to bevacizumab(BV)- it remains an open question. The measurement of serum vascular endothelial growth factor(VEGF) has been proposed as a predictive factor for this drug, even if literature data are contradictory. METHODS: We prospectively evaluated the role of BV, total and not BV-bound VEGF and angiopoietin-2(Ang-2) serum levels as potential predictive factors of response for BV in combination with an oxaliplatinbased chemotherapy. BV, Ang-2, total and not BVbound VEGF levels were measured at baseline, before 2^(nd) and 5^(th) cycle of oxaliplatin-based chemotherapy in 20 consecutive metastatic colorectal cancer patients. RESULTS: Results were correlated to response to treatment. Variability in BV levels have been found, with decreased level in less responding patients. In particular, the concentration of BV increased of 3.96 ± 0.69 folds in serum of responsive patients after 3 more cycles of therapy compared to those with stable or progressive disease with a 0.72 ± 0.25 and 2.10 ± 0.13 fold increase, respectively. The determination of free and total VEGF demonstrated that the ratio between the two values, evaluated immediately before the 2^(nd) and the 5^(th) cycle of therapy, decreased from 26.65% ± 1.33% to 15.50% ± 3.47% in responsive patients and from 53.41% ± 4.75 to 34.95% ± 2.88% in those with stable disease. Conversely, in those with progression of disease, the ratio showed the opposite behavior coming up from 25.99% ± 5.23% to 51.71% ± 5.28%. The Ang-2 levels did not show any relationship. CONCLUSION: Our data show that the ratio of not BV-bound VEGF to total VEGF serum and BV plasma concentrations for predicting the response to BV plus oxaliplatin-based chemotherapy could be a promising biomarker of response to BV. | Amalia Azzariti Letizia Porcelli Oronzo Brunetti Marzia Del Re Vito Longo Patrizia Nardulli Michele Signorile Jian-Ming Xu Angela Calabrese Anna Elisa Quatrale Evaristo Maiello Vito Lorusso Nicola Silvestris | 2016 | World Journal of Gastroenterology2016，22，27： | 4 |
| 3 | Target Therapies in Pancreatic Carcinoma显示文摘 | Nicola Silvestris Antonio Gnoni Anna Elisabetta Brunetti Leonardo Vincenti Daniele Santini Giuseppe Tonini Francesca Merchionne Evaristo Maiello Vito Lorusso Patrizia Nardulli Amalia Azzariti Michele Reni | 2014 | Current Medicinal Chemistry2014，，8： | 2 |
| 4 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial显示文摘 | Jean-Yves Douillard Rafael Rosell Mario De Lena Francesco Carpagnano Rodryg Ramlau Jose Luis Gonzáles-Larriba Tomasz Grodzki Jose Rodrigues Pereira Alain Le Groumellec Vito Lorusso Claude Clary Antonio J Torres Jabrail Dahabreh Pierre-Jean Souquet Julio A | 2006 | Lancet Oncology2006，，9： | 2 |
| 5 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study显示文摘 | Giancarlo Agnelli Gualberto Gussoni Carlo Bianchini Melina Verso Mario Mandalà Luigi Cavanna Sandro Barni Roberto Labianca Franco Buzzi Giovanni Scambia Rodolfo Passalacqua Sergio Ricci Giampietro Gasparini Vito Lorusso Erminio Bonizzoni Maurizio Tonato | 2009 | Lancet Oncology2009，，10： | 1 |
| 6 | Genotyping canine distemper virus (CDV) by a hemi-nested multiplex PCR provides a rapid approach for investigation of CDV outbreaks显示文摘 | Vito Martella Gabriella Elia Maria Stella Lucente Nicola Decaro Eleonora Lorusso Krisztian Banyai Merete Blixenkrone-M?ller Nguyen Thi Lan Ryoji Yamaguchi Francesco Cirone Leland Eugene Carmichael Canio Buonavoglia | 2007 | Veterinary Microbiology2007，，1： | 1 |
| 7 | Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non- small- cell lung cancer显示文摘 | Giuseppe Frasci Vito Lorusso Nicola Panza | 2002 | J Clin Oncol2002，18，13： | 1 |
| 8 | Duodenogastricreflux of bile acids,gasttrin and parietal cells,and gastric acid secretion before and 6 months after cholecystectomy显示文摘 | Dionigi Lorusso Giovanni Misciagna Vito Mangmi | 1990 | Ann J Surg1990，159，6： | 1 |
| 9 | Target-based therapies in breast cancer:current status and future perspoctives显示文摘 | Vito Lorusso | 2008 | Biologics2008，2，4： | 1 |
| 10 | Duodenogastficreflux of bile acids, gastrin and parietal cells, and gastric acid secretion before and 6 months after cholecystectomy 显示文摘 | Dionigi Lorusso Giovanni Misciagna Vito Mangini | 1990 | Am J Surg1990，159，6： | 1 |
| 11 | Bevacizumab in the treatment of Her2-negative breast cancer显示文摘 | Vito Lorusso | 2008 | Biologies2008，2，4： | 1 |
| 12 | Pharmacogenomics of cetuximab in metastatic colorectal carcinoma显示文摘 | Nicola Silvestris Bruno Vincenzi Anna Elisabetta Brunetti Fotious Loupakis Emanuela Dell’Aquila Antonio Russo Mario Scartozzi Riccardo Giampieri Stefano Cascinu Vito Lorusso Giuseppe Tonini Alfredo Falcone Daniele Santini | 2014 | Pharmacogenomics2014，，13： | 1 |
| 13 | Cholelithiasis in inflammatory bowel disease显示文摘 | Dionigi Lorusso Silvana Leo Ascanio Mossa Giovanni Misciagna Vito Guerra | 1990 | Diseases of the Colon & Rectum1990，，： | 1 |
| 14 | Cholelithiasis in inflammatory bowel disease显示文摘 | Dionigi Lorusso M.D. Silvana Leo M.D. Ascanio Mossa M.D. Giovanni Misciagna M.D. Vito Guerra Dipl. Stat | 1990 | Diseases of the Colon & Rectum1990，，9： | 1 |
| 15 | Role of gemcitabine in metastatic breast cancer patients: A short review显示文摘 | Nicola Silvestris Saverio Cinieri Ignazia La Torre Giuseppe Pezzella Gianmauro Numico Laura Orlando Vito Lorusso | 2007 | The Breast2007，，3： | 1 |
| 16 | Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis显示文摘 | Nicola Silvestris Mario Scartozzi Giusi Graziano Daniele Santini Vito Lorusso Evaristo Maiello Sandro Barni Saverio Cinieri Fotios Loupakis Salvatore Pisconti Anna Elisabetta Brunetti Giuseppe Palasciano Vincenzo Ostilio Palmieri Michela Del Prete Emanuel | 2015 | Expert Opinion on Biological Therapy2015，，2： | 1 |
| 17 | Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey显示文摘 | Salvatore Del Prete Saverio Cinieri Vito Lorusso Luigi Maiorino Carmine Pizza Agata Pisano Vincenzo Montesarchio Luigi Leo Clementina Savastano Giuseppe Pistolese Maddalena Bianco Roberto Mabilia Riccardo Tonachella Antonio Febbraro Luigi Manzione Salvato | 2014 | Future Oncol2014，，1： | 1 |
| 18 | Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: A clinical and laboratory diagnostic dilemma显示文摘 | Nicola Decaro Costantina Desario Gabriella Elia Marco Campolo Alessio Lorusso Viviana Mari Vito Martella Canio Buonavoglia | 2006 | Vaccine2006，，7： | 1 |
| 19 | A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal显示文摘 | Diana V. Golub A. Cahid Civelek Vivek R. Sharma Vito Lorusso | 2011 | Chemotherapy Research and Practice2011，，： | 1 |
| 20 | Duodenogastricreflux of bile acids,gasttrin and parietal cells,and gastric acid secretion before and 6 months after cholecystecto-my显示文摘 | Giovanni Misciagna MD Vito Mangmi | 1990 | Am J Surg1990，159，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员